One important HeSMO activity in the recent years is the support and execution of non-invasive, observational studies aiming to collect and process acquired data in order to create scientific recording data bases for various types of cancer. In that way, the results evaluation that obtained from processing and recording data from these clinical studies assist in accumulating important information about the prevalence of neoplastic diseases and the therapeutic management of neoplastic patients in Greece.

In this context, HeSMO has already completed an observational study for the management of patients with metastatic renal carcinoma in Greece between February 2012 and December 2014. Additionally, since May 2013, HeSMO has been linked to the European data base ENETS in order to record the neuroendocrine tumors (NET) in our country. At the same time, in a period crucial for the National Health System not only financially but also in principal, HeSMO, loyal to its social role, tries to ensure the necessary funding for high cost diagnostic tests concerning cancer patients in Greece.

In that way it funded the tests:

  • for the detection of EGFR mutations in patients with advanced/metastatic non- microcytic lung cancer. Through this service, from October 2011 till January 2015, 1250 patients from all over Greece were checked without any financial contribution of their own.
  • for the detection of gene re-arrangement in the prime-oncogene anaplastic lymphoma kinase (ALK) in specimens of patients suffering from non-microcytic, non oat-cell lung cancer. Through this service from May 2013 till October 2014 370 patients from all over Greece were checked without any financial contribution of their own.
  • for the detection of mutations of BRCA1/2 genes in 103 male patients with breast cancer, irrespective of age and family history, checked through EC funding in March 2013.
  • for the detection of mutations in exons 2,3,4 in KRAS and NRAS oncogenes in patients with metastatic colon cancer. Through this service, from December 2013 till June 2014, 500 patients from all over Greece were provided mutational analyses free of charge.

Currently, HeSMO provides analyses free of charge:

  • for the detection of mutations in exon 9 in cKIT gene in specimens of 27 GIST patients from all over Greece since April 2013.
  • for the detection of mutations of BRCA1/2 genes in 176 patients with ovarian cancer, irrespective of age and family history diagnosed in Greece from June 2014 onwards. This program has not been completed and still new patients are included in the protocol.